ATLANTA, GA – – (Globe Newswire – September 18, 2026) – – A shareholder class action lawsuit has been filed against Ardelyx, Inc. (“Ardelyx”) (NASDAQ: ARDX). The lawsuit alleges that Ardelyx made materially false and misleading statements about its two core drugs, IBSRELA and XPHOZAH.

If you purchased Ardelyx shares between January 13, 2025 and August 6, 2026, and experienced a loss on that investment, you are encouraged to discuss your legal rights by contacting Marshall P. Dees, Esq. at mdees@holzerlaw.com, by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/ardelyx/ for more information.

The deadline to ask the court to be appointed lead plaintiff in the case is November 16, 2026.